Citius Oncology Inc (CTOR) Quote

The company said they expect first sales in the first HALF of 2025, not in the first quarter.

True, the first quarter is IN the first half..... but I don't expect the launch until May or June. In biotech, when they say they "expect" something in the first half of a given year, it usually doesn't happen early.

What grant do they "need to finalize?" Can you provide more detail? I know about the NJ grant in March 2024 for $2.4M -- is there another one pending in 2025?

https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-secures-2-4-million-through-new-jersey-economic-development-program-302081639.html

I think the PPS is in a free-fall since Feb 24 because the Form 14 they filed on Feb 24 says they are increasing the A/S from 100M to 400M. Anticipated effective date: April 7th.

I doubt the insiders are dumping -- they paid over $2 per share and THEY are the ones who voted for the A/S increase (Directors, majority shareholders). I think that if they wanted to dump they would have done so before they decided to increase the A/S. Also, I believe all their options are priced higher than the current PPS.

Funding is a problem here, IMO. This company burned $6M last quarter and they have no cash ($112). Per the 10-Q, "The Company plans to continue to rely on funding from Citius Pharma." CTXR isn't rich either (about $1M in cash) and THEY burned $10M last quarter.

Citius expects to launch LYMPHIR in the first half of 2025 and they already have a Medicare J-Code so that is good. Looks like CTOR has a large inventory ($14M) ready to sell ("Inventory consists of finished goods of $6,134,895, and work in process of $8,246,474 as of December 31, 2024"). The question is going to be: how fast can they sell that inventory?

And when will Dr. Reddy's demand that $22M milestone payment? It's already past due. Maybe they are planning to pay Dr. Reddy in stock. From the 10-Q:At the time of the FDA approval for LYMPHIR, a $27.5 million milestone payment became payable under the terms of the asset purchase agreement for which a balance of $22.5 million remains due as of December 31, 2024. Pending further discussions with Dr. Reddy’s, Dr. Reddy’s agreed to a partial deferral without penalty of this milestone payment.

Maybe dilution to pay for everything to get it off the ground., ten dollars this year, maybe so.

Can't tell if stock is falling to let someone buy in or if just no support. Could be a buying opportunity. They need to finalize the grant it seems.

Quite possible, however:

Only if they sucessfully commercially launch their product LYMPHIR which they said will be in the ist half of 2025.

The reason it is so low, is the fact that the 92.2% owner of CTXR ( which spun off CTOR) board of directors is the same board of CTOR, and the CEO is the same. Whom IMO is a very poor manager and he is known to always move the goal posts further and further out.

CTXR the 92.2% owner (controlling CTOR) stock is selling at the lowest in it's history (split basis) due to the CEO's very bad management.

Also funding is a problem.

Anyone think this can hit ten dollars in 2025

CTOR...$1.23...🥳... https://schrts.co/ICqtBicz ...Bollie Squeeze is on...she gonna go up or down...

georgie18

Member Level
Re: georgie18 post# 388659

Thursday, January 16, 2025 3:28:33 PM

Post#
388694
of 390113
CTOR...$1.31...🥳...Trying for Upper Bollie Breakout...

georgie18

Member Level
Re: georgie18 post# 671469

Thursday, January 16, 2025 10:10:25 AM

Post#
671513
of 671603
CTOR...$1.13...🥳... https://schrts.co/gcbJpQsR ...Adding here on the Bullish Kicking Reversal Pattern...

georgie18

Member Level
Re: georgie18 post# 388592

Thursday, January 16, 2025 6:58:32 AM

Post#
388610
of 388659
CTOR...$1.28...🥳...Off my $1.09 Alert...

georgie18

Member Level
Re: None

Wednesday, January 15, 2025 2:15:10 PM

Post#
671415
of 671468
CTOR...Scaling in here on the $1.09 dip...🥳...Like the forward looking event...

CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

Thank you

The insider is CTXR the company that spun off CTOR. CTXR owns 92.3% of CTOR.

$CTOR How can this be a spam when insiders own more then 90% of the shares. They know something. CTOR Not to many shares left in the market. Should go up real fast when good news comes out. And it should be soon.
Shares Outstanding
71.55M
Public Float
3.93M

nice summary, launch any day now imo.

Post from MOMO's board, "Up and coming giant:

Citius Oncology (Nasdaq: CTOR)

"Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025."

LYMPHIR ( approved by the FDA for commercialization) is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175721086&txt2find=ctor

trying coiled up trying to break out of this range, can follow like the other one.

Yes Indeed...🥳

CTOR last Aug. 6th the price was $49.00 now $1.32

CTOR Not to many shares left in the market. Should go up real fast when good news comes out.
Total Insider Shares Held 64.72M
Citius Oncology Annual Shares Outstanding
(Millions of Shares)
2024 68M

Post from Stocktwits "$CTOR 400 million estimate for first release to market, this is with a majority still not set to offer lymphir as treatment. They have to as lymphir is the only approved treatment now for su sidies and so on. 400m initial. Insane, ez billion dollars valuation in 2 years time.

1.40's up :)

Demand growing into close,after mkt could be good

CTOR...$1.31...🥳...Trying for Upper Bollie Breakout...

georgie18

Member Level
Re: georgie18 post# 671469

Thursday, January 16, 2025 10:10:25 AM

Post#
671513
of 671603
CTOR...$1.13...🥳... https://schrts.co/gcbJpQsR ...Adding here on the Bullish Kicking Reversal Pattern...

georgie18

Member Level
Re: georgie18 post# 388592

Thursday, January 16, 2025 6:58:32 AM

Post#
388610
of 388659
CTOR...$1.28...🥳...Off my $1.09 Alert...

georgie18

Member Level
Re: None

Wednesday, January 15, 2025 2:15:10 PM

Post#
671415
of 671468
CTOR...Scaling in here on the $1.09 dip...🥳...Like the forward looking event...

CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

CTOR...................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

1.36's

1.20's up, only gave me partials at 1.14's in the morning :( Liking the forward events here. still got orders in jic they dip it again gl.

Your very welcome...🥳

Thanks georgie I picked up some 1.15 shares this morning.

CTOR...$1.13...🥳... https://schrts.co/gcbJpQsR ...Adding here on the Bullish Kicking Reversal Pattern...

georgie18

Member Level
Re: georgie18 post# 388592

Thursday, January 16, 2025 6:58:32 AM

Post#
388610
of 388659
CTOR...$1.28...🥳...Off my $1.09 Alert...

georgie18

Member Level
Re: None

Wednesday, January 15, 2025 2:15:10 PM

Post#
671415
of 671468
CTOR...Scaling in here on the $1.09 dip...🥳...Like the forward looking event...

CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

That would be nice...🥳

Zero borrow now,207% fee,could get really fun today

CTOR...$1.28...🥳...Off my $1.09 Alert...

georgie18

Member Level
Re: None

Wednesday, January 15, 2025 2:15:10 PM

Post#
671415
of 671468
CTOR...Scaling in here on the $1.09 dip...🥳...Like the forward looking event...

CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

CTOR...Scaling in here on the $1.09 dip...🥳...Like the forward looking event...

CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

Shares to short dropping,usually a tell of run up

Standard Fibonacci pullback,pattern continues up from here.

Gap filled and hit the bottom bolie(5day),higher high should start the chase up!

Today news,https://stocks.apple.com/Ab9gzALbjS4ilQFYvXP1zNQ

Just for your info. Forgot to attach in previous response.

Here is the link to the official fililing to the SEC filed on 12/27/2024 see page f4 for the income statement.

https://www.otcmarkets.com/filing/html?id=18074417&guid=IX0-keY-Hd5eJth

Personally i do not pay attention to charts.

Charts do not take into financial status,or any potential cataylts,earnins etc.The chart is solely based on programming and is based on current market conditions and changes as the the price goes up or down only.

They are strickly for trading.

I am a long term investor, and invest based on the the potential of the product, which i believe will be big.

But that is just me.

Thanks!,chart is bullish breakout,potential is astronomical,I bought the chart

It is incorrect.

They have no earnings. Always look at the financials. Schwab also say there are no financials. Svhwab does not have any but there are.

I posted a link to the financials.

My platform Charles Schwab info

????

Are you sure.

They have a loss of (-.31)

and a p/e of ( -4.4839)

https://www.otcmarkets.com/stock/CTOR/financials

What ever your looking at is incorrect.

They have no revenues and just went public as a spin off in 8/24, they do not have any earnings.

Price/earnings $5.37,earnings.24 per share,extremely undervalued

Buyout,merger,drug purchase from big pharma,something big coming when Jeffries is involved,this will get found!

Seriously, we went through that before.

I sent to you on another board:
CTOR isn't only a few million market cap.

The market cap is appox 105 million @$1.45

CTOR has 71,552,402 shares O/S a/0 9/30/2024, wheseas CTXR owns 92.2%.

See outstanding shares here (and on their Financials that were filed last week)

https://www.otcmarkets.com/stock/CTOR/security



https://www.otcmarkets.com/filing/html?id=18074417&guid=Q90-kqGyIgvnJth

Float is appox. 5.9 million.

$CTOR BULLISH ✨💎✨💎✨💎✨ Tomorrow breakout $2.00

(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

This is a high volume (279,379) for CTOR for the first hour of trading considering they have approx. 5.9 million share float.

This is 4.7% of the float with 5 1/2 hours of trading to go today.

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

January 06 2025 - 7:50AM
PR Newswire (US)

CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.

The engagement of Jefferies underscores Citius Oncology's commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.

"We are excited to partner with Jefferies, a leading global investment bank with deep expertise in the life sciences sector, to help us explore opportunities that align with our long-term vision. As we prepare to launch our first cancer therapy, now is an opportune time to review options that would be in the best interests of patients and shareholders," said Leonard Mazur, Chief Executive Officer of Citius Oncology. "Our goal is to deliver value to shareholders by making a meaningful impact in the oncology space."

Citius Oncology is committed to commercializing LYMPHIR™, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy.

The Company has not set a specific timeline for the strategic engagement and does not intend to disclose developments unless and until its Board of Directors has approved a specific transaction or course of action, or the company otherwise determines that disclosure is appropriate or necessary. There can be no assurance, however, that this process will result in a strategic transaction or other alternative.

About LYMPHIR™ (denileukin diftitox-cxdl)

LYMPHIR is a targeted immune therapy for relapsed or refractory CTCL indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.

In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia. LYMPHIR was approved by the FDA in August 2024.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.

https://ih.advfn.com/stock-market/NASDAQ/citius-oncology-CTOR/stock-news/95198794/citius-oncology-engages-jefferies-as-exclusive-fin

$CTOR

ctor.......................................https://stockcharts.com/h-sc/ui?s=ctor&p=W&b=5&g=0&id=p86431144783

No problem.

Happens to everyone.

I don't know why OTCM shows the wrong o/s it's my mistake not to dig into the DD

Just my opinion:

It will be a banner year for CTOR, with the expected 1st sales in the 1st QTR. 2025 for :

LYMPHIR™ (denileukin diftitox-cxdl) Injection 300 mcg.

NOW FDA APPROVED

LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.